HOOKIPA PharmaHOOK 49 Beneish M-Score is -4.52 as of Jun. 25, 2026. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 831 Biotechnology companies, HOOKIPA Pharma ranks better than 91.94% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -4.52 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for HOOKIPA Pharma's Beneish M-Score or its related term are showing as below:
HOOK'
s Beneish M-Score Range Over the Past 10 Years
Min: -4.92 Med: -2.43 Max: 4.99
Current: -4.52
During the past 8 years, the highest Beneish M-Score of HOOKIPA Pharma was 4.99. The lowest was -4.92. And the median was -2.43.
HOOKIPA Pharma Beneish M-Score Related Terms
HOOKIPA Pharma Beneish M-Score Historical Data
* Premium members only.
The historical data trend for HOOKIPA Pharma's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOOK vs LNAI, ZEOX, GDTC: Beneish M-Score Comparison
For the Biotechnology subindustry, HOOKIPA Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOOKIPA Pharma Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where HOOKIPA Pharma's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of HOOKIPA Pharma for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.479
+
0.528 * 1
+
0.404 * 0.2128
+
0.892 * 0.2848
+
0.115 * 0.2538
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 4.8039
+
4.679 * -0.165218
-
0.327 * 1.0225
=
-4.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(3.119 / (3.119 + 12.02))
/
(2.252 / (2.252 + 0.522))
=
0.206024
/
0.811824
=
0.2538
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-56.004 - -1.769
-
-45.527)
/
52.706
=
-0.165218
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
HOOKIPA Pharma has a M-score of -4.52 suggests that the company is unlikely to be a manipulator.
HOOKIPA Pharma (HOOK) has a Beneish M-Score of -4.52 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #67 out of 831 companies in the Biotechnology industry, placing it in the top 8.1%.
Is HOOKIPA Pharma's Beneish M-Score too high?
HOOKIPA Pharma's current Beneish M-Score is -4.52. Based on the distribution chart, HOOKIPA Pharma ranks #67 out of 831 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Beneish M-Score compare to LNAI and ZEOX?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #67 out of 831 companies for Beneish M-Score. This places HOOKIPA Pharma in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Beneish M-Score is -4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current Beneish M-Score is -4.52. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Beneish M-Score is -4.52 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOOKIPA Pharma (HOOK) Overvalued in 2026?
Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued.
The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78.
GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.
Key valuation signals for HOOK:
Beneish M-Score: -4.52
GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score
Get the complete analysis for HOOK
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOOK has been successfully added to your 
